文献速递结核与非结核分枝杆菌细菌感染、耐药与抗菌药物

南非耐药结核患者利奈唑胺耐药与治疗失败

Linezolid resistance in patients with drug-resistant TB and treatment failure in South Africa.
PubMed 文献 · J Antimicrob Chemother · 2019-01-01

对55株分离株行MIC检测和rrl/rplC测序,16株表型耐药株均携带已知耐药突变,最常见为rplC T460C(10株),MIC≤临界浓度的菌株未检出突变。

要点

  • 利奈唑胺方案治疗失败的耐药结核患者中约三分之一出现利奈唑胺耐药。
  • 耐药出现较晚,中位用药22个月后发生。
  • rplC T460C是最常见的耐药突变,rrl突变包括G2814T、G2270C/T和A2810C。

核心结论

  • 耐药结核患者含利奈唑胺方案治疗失败时,约三分之一出现表型或基因型利奈唑胺耐药,且耐药发生较晚。
  • 表型耐药与rrl和rplC的有限几种突变相关,MIC≤临界浓度的菌株未检出突变。

研究设计与样本

  • 回顾性研究,在南非两个公立机构纳入含利奈唑胺方案治疗失败(培养阳性≥4个月)的成人和青少年耐药结核患者。

主要发现

  • 16株表型耐药分离株均携带已知耐药突变,最常见为rplC T460C(10株)。
  • rrl突变包括G2814T、G2270C/T和A2810C。
  • MIC≤临界浓度的分离株未检出突变。

关键数值与推荐

  • 表型耐药定义为利奈唑胺MIC>1 mg/L。
  • 治疗失败定义为培养阳性≥4个月。

临床怎么用

  • 对含利奈唑胺方案治疗4个月后培养阳性的耐药结核患者,应考虑进行基因型耐药筛查以优化治疗并避免无效利奈唑胺的毒性。

局限性

  • 未报告其他临床因素与耐药的关联分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Limited data exist on clinical associations and genotypic correlates of linezolid resistance in Mycobacterium tuberculosis. We aimed to describe mutations and clinical factors associated with phenotypic linezolid resistance from patients with drug-resistant TB at two public sector facilities in South Africa. METHODS: Adults and adolescents with treatment failure (culture positivity ≥4 months) on a linezolid-containing regimen were retrospectively identified. Phenotypic resistance, as defined by a linezolid MIC >1 mg/L, was assessed for retrieved isolates using broth microdilution. Targeted sequencing of rrl and rplC was performed, irrespective of growth on subculture. RESULTS: Thirty-nine patients with linezolid-based treatment failure were identified, 13 (33%) of whom had phenotypic or genotypic linezolid resistance after a median duration of 22 months (range = 7-32) of linezolid therapy. Paired MIC testing and genotyping was performed on 55 unique isolates. All isolates with phenotypic resistance (n = 16) were associated with known resistance mutations, most frequently due to the T460C substitution in rplC (n = 10); rrl mutations included G2814T, G2270C/T and A2810C. No mutations were detected in isolates with MICs at or below the critical concentration. CONCLUSIONS: Linezolid resistance occurred in a third of patients with drug-resistant TB and treatment failure. Resistance occurred late and was predicted by a limited number of mutations in rrl and rplC. Screening for genotypic resistance should be considered for patients with a positive culture after 4 months of linezolid therapy in order to optimize treatment and avoid the toxicity of ineffective linezolid therapy.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Wasserman S, Louw G, Ramangoaela L, et al. Linezolid resistance in patients with drug-resistant TB and treatment failure in South Africa. J Antimicrob Chemother. 2019. PMID: 31081017. doi:10.1093/jac/dkz206

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。